Abstract
The presence of small amounts of circulating DNA in plasma was demonstrated 60 years ago. Since then, cellfree DNA has been tested for quantity, fragmentation pattern and tumor-specific sequences in patients with various malignancies. The introduction of improved detection methods showed that all these alterations are regularly detectable in many cancer patients and the investigation of cell-free DNA may provide useful diagnostic and prognostic information. Herein, we review the recent findings on cell-free DNA alterations in patients with prostate cancer and discuss its diagnostic and prognostic potential.
Keywords: Prostate cancer, DNA fragmentation, cell-free DNA, DNA methylation, allelic imbalance.
Current Cancer Therapy Reviews
Title:Diagnostic und Therapeutic Value of Cell-free Circulating DNA as a Non-invasive Biomarker in Patients with Prostate Cancer
Volume: 9 Issue: 4
Author(s): Stefan Latz, Stefan C. Muller and Jorg Ellinger
Affiliation:
Keywords: Prostate cancer, DNA fragmentation, cell-free DNA, DNA methylation, allelic imbalance.
Abstract: The presence of small amounts of circulating DNA in plasma was demonstrated 60 years ago. Since then, cellfree DNA has been tested for quantity, fragmentation pattern and tumor-specific sequences in patients with various malignancies. The introduction of improved detection methods showed that all these alterations are regularly detectable in many cancer patients and the investigation of cell-free DNA may provide useful diagnostic and prognostic information. Herein, we review the recent findings on cell-free DNA alterations in patients with prostate cancer and discuss its diagnostic and prognostic potential.
Export Options
About this article
Cite this article as:
Latz Stefan, Muller Stefan C. and Ellinger Jorg, Diagnostic und Therapeutic Value of Cell-free Circulating DNA as a Non-invasive Biomarker in Patients with Prostate Cancer, Current Cancer Therapy Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/157339470904140418094329
DOI https://dx.doi.org/10.2174/157339470904140418094329 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine Genetics and Bioenergetics of Mitochondria Influencing the Etiology and Pharmacology of Steroidal Hormones
Current Pharmacogenomics Molecular Modelling, Design, Synthesis and Biochemical Evaluation of a Range of Non-Steroidal Thiosemicarbazone-Based Inhibitors of Estrone Sulfatase (ES) - A Potential Insight into the Action of a Range of Allosteric Inhibitors of ES
Letters in Drug Design & Discovery Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Stress-Activated MAP Kinase Cascades in Cellular Senescence
Current Medicinal Chemistry Chemoprevention of Lung Pathologies by Dietary n-3 Polyunsaturated Fatty Acids
Current Medicinal Chemistry Rational Design of Non-Hydroxamate Histone Deacetylase Inhibitors
Mini-Reviews in Medicinal Chemistry Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine Promising Targets in Anti-cancer Drug Development: Recent Updates
Current Medicinal Chemistry Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives
Current Drug Metabolism Assessment of Gene Transfer Using Imaging Methodology
Current Genomics Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Bisacylimidoselenocarbamates Cause G2/M Arrest Associated with the Modulation of CDK1 and Chk2 in Human Breast Cancer MCF-7 Cells
Current Medicinal Chemistry Subject Index To Volune 2
Current Cancer Therapy Reviews Liposomes as siRNA Delivery Vectors
Current Drug Metabolism Inflammation in Neurodegenerative Disorders: Friend or Foe?
Current Aging Science AR Copy Number and AR Signaling-directed Therapies in Castrationresistant Prostate Cancer
Current Cancer Drug Targets Patent Review
Combinatorial Chemistry & High Throughput Screening miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy The Effects of Italian Mediterranean Organic Diet (IMOD) on Health Status
Current Pharmaceutical Design